Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | PKM | P14618 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768578 | 0.89 | PKM (0.70) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL17029140 | 0.85 | POLB (0.72) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL24322686 | 0.84 | MEN1 (0.59) | GAAALDH1A1KMT2APKMLMNA | |
| SCHEMBL24323815 | 0.84 | PKM (0.67) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL30754632 | 0.83 | ALDH1A1 (0.68) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL20300422 | 0.83 | PKM (0.71) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL12518923 | 0.83 | GAA (0.72) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL10722317 | 0.82 | GAA (0.62) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL6744239 | 0.80 | ALDH1A1 (0.71) | GAAALDH1A1KMT2APKMNPC1 | |
| SCHEMBL28784026 | 0.79 | ALDH1A1 (0.69) | GAAALDH1A1KMT2APKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | GAA 1981/4885ALDH1A1 4556/4885KMT2A 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.